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The aims of this study were to determine the associations between anemia of critical illness, erythropoietin stimulating agents
(ESA), packed red blood cell transfusions and varying degrees of renal dysfunction with mortality, and ICU- and hospital
length of stay (LOS). This was a cross-sectional retrospective study of 5,314 ICU patients from USA hospitals. Hospital, patient
demographics, and clinical characteristics were collected. Predictors of mortality and hospital and ICU LOS were evaluated using
multivariate logistic regression models. The mean ICU admission hemoglobin in this study was 9.4 g/dL. The prevalence of ESA
use was 13% and was associated with declining renal function; 26% of the ICU patients in this study received transfusion. ESA
utilization was associated with 28% longer hospital LOS (P < 0.001). ICU LOS was increased by up to 18% in patients with eGFR
rates of <30 and 30–59 mL/min/1.73 m2 , respectively (P < 0.05) but not in those receiving dialysis. Mortality was significantly
associated with renal dysfunction and dialysis with odds ratios of 1.94, 2.66 and 1.40 for the dialysis, and eGFR rates of <30 and
30–59 and mL/min/1.73 m2 , respectively (P < 0.05). These data provide a snapshot of anemia treatment practices and outcomes
in USA ICU patients with varying degrees of renal dysfunction.

1. Introduction
Anemia of critical illness (ACI) has been estimated to occur
in up to 50% of patients admitted to the intensive care unit
(ICU) [1–3]. Of further concern, following three days or
longer in the ICU, nearly all patients will have developed
anemia [1]. This often requires intervention, such as packed
red blood cell (PRBC) transfusions or, until recently, pharmacological management with an erythropoietin stimulating
agent (ESA). Both treatment options, while having varying
degrees of eﬃcacy in this population, carry substantial risks
for morbidity and mortality [3–7].
The pathophysiology of ACI is complex and multi-factorial. Concurrent inflammation, renal dysfunction, blood
loss from surgery, phlebotomy, and/or the gastrointestinal
tract, coagulopathy, and bone marrow suppression are but

a few of the many potential causes of ACI [8]. The clinical
consequences of ACI are important; lack of adequate tissue
oxygenation can contribute to cardiopulmonary failure,
morbidity, mortality, and increased hospital length of stay
(LOS).
To date the major thrust of research has focused on identifying appropriate hemoglobin (Hb) treatment triggers and
restrictive transfusion strategies and developing evidencebased guidelines for anemia management [9, 10]. While these
are clearly important initiatives, they require well-designed,
controlled clinical trials that may take years to complete. In
the meantime, there remains a paucity of data regarding what
happens in “real world” ICU environments across the United
States.
To this end, we conducted a large epidemiological study
of ACI across hospitals in the USA and evaluated patient
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and hospital demographics, renal function, ESA and PRBC
usage, and clinical outcomes such as mortality, and ICU and
hospital LOS.

2. Materials and Methods
This was a cross-sectional, population-based, retrospective
study using the Solucient ACTracker database to determine
the associations between ACI and renal dysfunction with
three major outcome variables: mortality, and ICU and
hospital LOS. The database contained approximately 10.5
million patient discharges from 550 hospitals nationwide.
Thirty-three of the participating hospitals provided a complete set of laboratory data, drug utilization, hospital procedures, and patient outcomes data that were included in the
final analysis. All data were deidentified to protect patient
confidentiality. The study was approved by the Virginia
Commonwealth University Institutional Review Board.
2.1. Study Population. Patients were included if they had
an ICU admission of at least 24 hours between January
2001 and December 2005, were at least 18 years of age,
had a hemoglobin (Hb) and serum creatinine (SCr) level
obtained within 72 hours of hospital admission, or had
a procedure code for dialysis (procedure code 39.95 (hemodialysis), 54.98 (peritoneal)). Exclusion criteria included
patients with anemia of neoplastic diseases (285.22) or
those receiving chemotherapy (V58.1). Patients with an
admission Hb <12 g/dL were included in the final analysis
and were grouped based on estimated glomerular filtration
rate (eGFR) using the MDRD equation [11], which was
categorized as >60, 30–59, <30 mL/min/1.73 m2 , and those
receiving dialysis, respectively.
2.2. Data Collection. The pertinent study data included
hospital characteristics, patient demographics and disposition, severity of illness determined using Refined Diagnosis
Related Group codes [12, 13], hospital and ICU LOS, ESA
and PRBC transfusion usage based on prescriber orders, and
admission Hb and SCr values.
2.3. Statistical Analyses. Descriptive statistics, including
mean ± standard deviation (SD) and median (interquartile
range), were used to characterize the central tendency and
dispersion of continuous variables. Categorical variables
were expressed as frequency and percentage within each
category, and they were analyzed for significance by Pearson’s
chi-squared test. Diﬀerences in LOS were compared with
respect to ESA and PRBC transfusion status with analysis
of variance (ANOVA). There were 457 (2.4%) patients with
missing ethnicity information in the database, and these
patients were considered African-American for the purposes
of calculating eGFR. There were 44 (0.23%) patients missing
ICU LOS data, and these patients were excluded from the
LOS analyses. To examine the eﬀects of renal function
status on hospital length of stay and mortality, regression
analyses were conducted while controlling for potential
confounding variables (including age, race, sex, ICU LOS,
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Table 1: Hospital characteristics.
Parameter
All hospitals
Teaching hospitals
Hospital beds
<200
200–299
300–499
≥500
US geographic region
Northeast
Midwest
South
West

N (%)
33 (100)
5 (15)
14 (42)
9 (27)
4 (12)
6 (19)
15 (46)
6 (18)
10 (30)
2 (6)

ESA use, transfusion status, mechanical ventilation or CPAP
status, vasopressor use, severity of illness, and presence
of following comorbid conditions: GI bleed, sepsis, and
neurologic injury). Logistic regression was used for mortality
estimates, and a generalized linear model with a normal
distribution and a log link was used for the LOS analyses.
In both cases, robust estimates of standard errors were
calculated by clustering on hospitals. This was done to allow
for a potential violation of independence among patients
who were admitted to the same hospital. Data analysis was
performed using Stata/SE version 11 (StataCorp LP, College
Station, TX, USA) with a P value of <0.05 representing
statistical significance.

3. Results
3.1. Hospital Characteristics. Thirty-three U.S. hospitals provided patient laboratory and clinical outcome data for this
study (Table 1). The majority were classified as nonteaching
hospitals with <200 beds. Nineteen percent of hospitals
had >500 beds. The northeast USA had the most hospitals
represented while the western USA had the least.
3.2. Patient Characteristics. The complete dataset contained
19,009 patients who had an ICU admission, SCr and Hb
value. Of this total, 5,314 (28%) of these patients met
the criteria for anemia (admission Hb < 12 g/dL). Table 2
provides the population demographics. The mean age was
69.2 years however the age varied based on eGFR criteria. The
majority of the study population was female and Caucasian.
The mean baseline Hb was 9.4 g/dL for the study population,
which was consistent across eGFR groups. Ninety-three
percent of the population was directly admitted into an
ICU environment (Table 3). Overall the majority of the
study population admissions were classified as “Emergency”
(53.6%) with the most frequent site of care being the medical
ICU (66.4%). Only 376 (7%) of the population was not
initially admitted to the ICU. The two most common severity
of illness classifications for the population were “moderate”
(33.5%) and “major” (35.1%); approximately 16% of the
population was classified as “extreme” severity of illness.
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Table 2: Baseline patient characteristics based on eGFR (mL/min/1.73 m2 ).

Mean age, y (SD)
Gender, female, n (%)
Ethnicity, n (%)
White
Black
Other
Mean Hb, g/dL (SD)
Mean eGFR, (SD)
Mean SCr mg/dL (SD)

Overall
(n = 5314)
69.2 (15.0)
2861 (53.8)
4394 (82.7)
729 (13.7)
191 (3.6)
9.4 (1.2)
59.0 (39.9)
1.9 (1.9)

(n = 2285)
65.1 (16.5)
1179 (51.6)

30–59
(n = 1705)
73.6 (12.0)∗
959 (56.3)∗

<30
(n = 1085)
72.0 (13.4)∗
609 (56.1)∗

Dialysis
(n = 239)
64.5 (15.8)
114 (47.7)∗

1874 (82.0)
334 (14.6)
77 (3.4)
9.5 (1.4)
93.6 (35.5)
0.8 (0.2)

1473 (86.4)
182 (10.7)
50 (2.9)
9.4 (1.3)
45.1 (8.7)∗
1.5 (0.3)∗

889 (81.9)
147 (13.6)
49 (4.5)
9.2 (1.4)∗
18.4 (7.2)∗
3.8 (2.2)∗

158 (66.1)
66 (27.6)
15 (6.3)
9.4 (1.2)
N/A
6.2 (3.1)∗

≥60

∗

P < 0.001 compared to eGFR > 60 mL/min/1.73 m2 .

Seven hundred fifteen of 5,314 patients (13%) received ESA
treatment while hospitalized. ESA usage was associated with
declining eGFR and HD classification (N = 117 (5%), 118
(7%), 222 (22.2%), and 94 (47%) for each eGFR category
and HD group, resp.). Comparatively, 1,398 (26%) patients
received PRBC transfusion, and usage was consistent across
eGFR (N = 526 (24%), 446 (27%), 238 (23.8%), and 26
(13%) for each eGFR and HD group, resp.).
3.3. Length of Stay and Mortality. Neither ESA nor PRBCs
were associated with longer ICU LOS (Tables 4(a) and
4(b)). However, those classified in the eGFR categories of
30–59 and <30 mL/min/1.73 m2 had nearly 18 and 17%
longer ICU LOS, respectively, compared to those with eGFR
>60 mL/min/1.73 m2 (P < 0.005). Patients receiving ESAs
had 28.4% longer hospital LOS (95% CI 14.6–43.9%, P <
0.001). Conversely, neither eGFR classification nor PRBC
transfusion impacted total hospital LOS. Declining renal
function and dialysis were the only variables significantly
associated with increased mortality risk compared to those
with eGFR >60 mL/min/1.73 m2 (Table 5).

4. Discussion
This study assessed anemia treatment practice patterns and
associated clinical outcomes across a geographically diverse
population of critically ill patients with varying degrees
of renal dysfunction. While clinicians typically consider
ACI a consequence of prolonged hospitalization, this study
suggests that the prevalence of baseline anemia upon ICU
admission is relatively common, approximately 28% of all
ICU patients in this database study.
The study period ranged from 2001 to 2005, a time
frame when ESA use was being actively evaluated in critically
ill patients [4, 14, 15]. During this period, ESA use was
proposed to reduce the number of PRBC transfusions and
their associated morbidity. An interesting finding was that
despite the relatively high baseline severity of illness and
presence of mean Hb values of approximately 9.5 g/dL
across all renal dysfunction groups, merely 13% of patients

received ESA treatment. Low prevalence of ESA use in nonICU, hospitalized patients has been shown previously [16].
Conversely, 26% received at least one PRBC transfusion,
which was lower than previously published literature [2, 3,
14]. This is most likely explained by the mean baseline Hb
of >9.0 g/dL across all groups. In many hospitals, the typical
transfusion trigger is now 7 g/dL based on data by Hebert
[17].
There were marked diﬀerences in the univariate and
multivariate LOS results. The univariate results suggested
that ESA usage was associated with longer ICU and hospital
LOS; however when adjusted for patient severity and other
factors, ESA usage was only associated with a 28% longer
hospital LOS (Table 4(a)). Whether this was directly related
to ESA use is impossible to know given the observational
nature of this study. In fact the opposite could be argued in
that the sicker patients with longer LOS were more likely to
have an ESA intervention attempted. However, Corwin et al.
previously found no increased ICU LOS associated with ESA
utilization [4]. ESA use was not found to impact mortality
in our study. However, previous subgroup analyses from
prospective trials have suggested critically that ill trauma
patients may have mortality benefit from recombinant erythropoietin [4, 14, 15]. Comparatively our study population
contained merely 4% trauma surgery patients; therefore the
dataset was not ideal to compare to previously published
data.
This study found no association between PRBC utilization and increased LOS or mortality. In fact, there were
few diﬀerences in LOS between those who received PRBCs
and those who received no treatment. Previous prospective
cohort studies have found a positive association between
PRBC transfusion and LOS and mortality [2, 3, 5]. The
disparate findings are likely the result of diﬀerent study
populations (e.g., less trauma in our study), diﬀering levels
of severity of illness, and diﬀering degrees of anemia. A
limitation of this dataset, unlike previously published trials,
was that it did not quantify the number of PRBC transfusions
patients received. Therefore if a “dose-response” existed
between PRBC quantity, LOS, and mortality, we would not
be able to identify this trend.
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Table 3: Admission characteristics based on eGFR (mL/min/1.73 m2 ).

Admission type, n (%)
Elective/routine
Emergency
Urgent
Unknown
Admission, n (%)
ICU
Medical
Trauma surgery
Nontrauma surgery
Non-ICU
Medical
Trauma surgery
Non-trauma surgery
Severity of Illness, n (%)
Minor
Moderate
Major
Extreme

Overall
(n = 5314)

≥60
(n = 2285)

30–59
(n = 1705)

<30
(n = 1085)

Dialysis
(n = 239)

971 (18.3)
2849 (53.6)
988 (18.6)
506 (9.5)

563 (24.6)
1047 (45.8)
429 (18.8)
246 (10.8)

285 (16.7)
988 (57.9)
281 (16.5)
151 (8.9)

96 (8.9)
669 (61.7)
224 (20.7)
96 (8.9)

27 (11.3)
145 (60.7)
54 (22.6)
13 (5.4)

1245 (58.3)
121 (5.7)
770 (35.1)

1090 (68.7)
61 (3.8)
436 (27.5)

781 (78.3)
9 (0.9)
207 (20.8)

161 (75.2)
5 (2.3)
48 (22.4)

74 (50.3)
8 (5.4)
65 (44.2)

62 (53.5)
7 (6.0)
47 (40.5)

55 (62.5)
2 (2.3)
31 (35.2)

14 (56.0)
0
11 (44.0)

P
<0.001

4934 (93)
3277 (66.4)
196 (4.0)
1461 (29.6)
376 (7)
205 (54.5)
17 (4.5)
154 (41.0)

<0.001

0.462

<0.001
834 (15.7)
1782 (33.5)
1866 (35.1)
832 (15.7)

405 (17.7)
659 (28.8)
855 (37.4)
366 (16.0)

234 (13.7)
614 (36.0)
568 (33.3)
289 (16.9)

178 (16.4)
406 (37.4)
355 (32.7)
146 (13.5)

17 (7.1)
103 (43.1)
88 (36.8)
31 (12.9)

Table 4
(a) Association between eGFR category, ESA use, and transfusion status in hospital LOS

Unadjusted data
Relative change (95% CI)
eGFR range
Dialysis
<30
30–59
≥60
ESA use
PRBC

16.6% (−0.03–40.0%)
0.02% (−0.07–12.9%)
−0.01% (−0.08–6.8%)
—
94.9% (74.9–117.1%)
−0.11% (−0.20–0.01%)

P
0.095
0.620
0.837
—
<0.001
0.028

Adjusted data∗
Relative change (95% CI)
0.06% (−0.12–28.7%)
0.02% (−0.12–19.7%)
0.01% (−0.10–14.5%)
—
28.4% (14.6–43.9%)
0.01% (−0.07–8.9%)

P
0.537
0.763
0.819
—
<0.001
0.914

∗

Adjusted for mortality, age, race, sex, ICU LOS, anemia status, ESA use, transfusion status, mechanical ventilation status, CPAP status, vasopressor use,
severity of illness, and presence of, following comorbid conditions, GI bleed, sepsis, acute renal failure, and neurologic injury.
(b) Association between eGFR category, ESA use, and transfusion status in ICU LOS

Unadjusted data
Relative change (95% CI)
eGFR range
Dialysis
<30
30–59
≥60
ESA use
PRBC
∗

0.06% (−0.22–13.3%)
0.03% (−0.06–12.5%)
0.04% (−0.04–12.5%)
—
96.3% (71.7–124.4%)
0.16% (−0.26–0.04%)

P
0.505
0.535
0.379
—
<0.001
0.008

Adjusted data∗
Relative change (95% CI)
0.04% (−0.17–29.0%)
17.9% (0.07–29.7%)
16.8% (0.05–30.1%)
—
0.04% (−0.07–15.8%)
0.01% (−0.08–10.9%)

P
0.757
0.001
0.005
—
0.479
0.855

Adjusted for mortality, age, race, sex, ICU LOS, ESA use, transfusion status, mechanical ventilation status, CPAP status, vasopressor use, severity of illness,
and presence of, following comorbid conditions, GI bleed, sepsis, acute renal failure, and neurologic injury.
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Table 5: Odds ratios for mortality based on eGFR, ESA, and PRBC treatment.
Unadjusted data
OR (95% CI)

Adjusted data∗
OR (95% CI)

P

P

(mL/min/1.73 m2 )

eGFR
Dialysis
<30
30–59
≥60
ESA treatment
PRBC treatment

1.4 (0.87–2.20)
3.1 (2.46–3.89)
1.6 (1.37–1.92)
—
1.1 (0.79–1.53)
0.91 (0.67–1.25)

0.164
<0.001
<0.001
—
0.587
0.571

1.94 (1.22–3.08)
2.66 (2.05–3.45)
1.40 (1.20–1.66)
—
0.86 (0.43 –1.72)
1.10 (0.82 –1.38)

0.005
<0.001
<0.001
—
0.674
0.641

∗

Adjusted for age, race, sex, ICU LOS, ESA use, transfusion status, mechanical ventilation or CPAP status, vasopressor use, severity of, illness, and presence
of, following comorbid conditions, GI bleed, sepsis, and neurologic injury.

The presence of baseline renal dysfunction was associated
with prolonged hospital and ICU LOS and mortality. While
this has been known for some time, even mild renal dysfunction, 30–59 mL/min/1.73 m2 , appeared to have a 40%
increased mortality risk in this population. Interestingly
there was no association between dialysis and increased
LOS; however there were relatively few dialysis patients in
the study population, therefore impacting the robustness of
these data.
There are unavoidable limitations to this database study.
A potential limitation is the external validity of these
data to large, level 1 trauma centers. This database was
comprised of primarily smaller, nonteaching institutions.
This likely impacted the inclusion of more trauma patients
as well as those with increased severity of illness. However,
while there is a notion that there are diﬀerences between
relatively smaller and larger teaching hospitals, there were
no published data to support this notion. Similarly the geographic location of sites was more heavily weighted towards
the northeast and southern USA. There is a possibility
that anemia treatment practice patterns and transfusion
thresholds diﬀer across the USA. Third, database studies in
general do not provide investigators with patient level data,
such as ESA dose or PRBC units received, administration
schedule, social history, or pertinent past medical history.
Fourth, eGFR was used as a means of stratifying the anemia
population. While it is debatable how accurately the eGFR
estimates kidney function in critically ill patients, this served
as a convenient means by which to stratify patient groups.
Lastly, the potential for errors (e.g., clerical entry, hospital
coding errors) in the database used for this study cannot be
ignored.

5. Conclusion
In this cohort of anemic critically ill patients, the presence
of baseline kidney dysfunction (eGFR < 60 mL/min/1.73 m2 )
upon ICU admission was associated with significantly prolonged ICU LOS and mortality. Twice as many patients
received transfusion compared to ESA treatment. Blood
transfusion was not associated with mortality or increased
LOS. While ESA treatment was associated with a 28% longer
hospitalization, these patients appeared to be more severely

ill. Further prospective trials are needed to determine the best
patient candidates for anemia treatment interventions in the
ICU.
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